Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 88.7%

Neg 88.7% Neu 0% Pos 0%

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.